Equities

Private Rented Sector SA

RNT:WSE

Private Rented Sector SA

Actions
TechnologyTechnology
  • Price (PLN)5.50
  • Today's Change0.50 / 10.00%
  • Shares traded1.66k
  • 1 Year change-30.38%
  • Beta--
Data delayed at least 15 minutes, as of May 24 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Perma Fix Medical SA, formerly CEE Opportunity Partners Poland SA is a Poland-based company engaged in transaction financing. The Company specializes in equity line financing (ELF) and venture capital investments in the area of life sciences, new technologies and real estate. Its investment strategy is based on investing in public companies with financing period up to three years, funding from one to 30 million dollars and shareholder's exiting shares as transaction collateral. On November 18, 2013, CEE Opportunity Partners LLC acquired 62.86% stake in the Company. In April 2014, Perma-Fix Environmental Services Inc. acquired an 80% stake in the Company.

  • Revenue in PLN (TTM)200.00k
  • Net income in PLN27.20k
  • Incorporated2011
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Private Rented Sector SA200.00k27.20k7.27m--267.12--77.5136.340.02060.02060.1514-0.0351.79--2.20--24.281,266.23----23.89-1,935.5513.602,755.44-------------66.26------
Inno-Gene SA1.13m-1.46m10.18m27.00--1.54--9.02-0.2559-0.25590.19791.160.10864.670.673---14.047.92-19.0710.7339.1873.63-129.3411.592.58--0.0362---93.08-16.73-542.12------
Sygnis SA14.50m-6.24m15.75m33.00--0.3678--1.09-0.2742-0.27420.63761.700.20030.8476.52---8.88-6.10-16.72-9.5754.8556.46-44.34-22.440.530-7.570.0739---33.3844.26-266.18------
Braster SA319.00k-4.75m16.24m10.00------50.91-0.1647-0.16470.011-0.15070.0160.00398.0831,900.00-23.81-29.93-252.42-72.5494.3679.59-1,488.40-1,124.890.306-2.921.64---88.96-18.1128.68------
Genxone SA2.01m-3.75m19.78m----1.40--9.83-1.14-1.140.61064.280.121213.035.82---22.6114.58-23.4616.46-32.2948.42-186.5020.4118.23--0.0034---77.38111.39-874.87---28.78--
Stem Cells Spin SA372.16k-204.45k19.84m1.00--2.7222.2653.31-0.005-0.0050.0090.17660.02670.07412.08372,160.00-1.47-1.14-2.37-1.9388.1494.37-54.94-45.360.014-47.230.0055--68.84-4.37-680.05---52.67--
Nanogroup SA2.02k-7.89m20.30m----4.53--10,048.73-0.3926-0.39260.00010.22280.000217.600.0349---56.82-23.18-67.19-26.06-47,764.85-278.03-391,395.10-1,567.570.5186-2,409.120.00---98.55-55.07-840.84---8.99--
Pure Biologics SA-100.00bn-100.00bn23.91m29.00---------------0.9246-----------48.68---83.38--38.81---195.73----1.30--160.63-7.58-117.62------
Cannabis Poland SA199.93k-675.76k33.11m----60.80--165.63-0.0255-0.02550.00760.01110.30180.82645.07---102.76-116.92-175.94-136.3026.1612.29-340.53-959.391.35-45.880.2547---47.5550.2314.30------
Data as of May 24 2024. Currency figures normalised to Private Rented Sector SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.